Latest news
25 items- SECSEC Form 25-NSE filed by NexImmune Inc.25-NSE - NexImmune, Inc. (0001538210) (Subject)
- SECSEC Form EFFECT filed by NexImmune Inc.EFFECT - NexImmune, Inc. (0001538210) (Filer)
- SECSEC Form S-8 POS filed by NexImmune Inc.S-8 POS - NexImmune, Inc. (0001538210) (Filer)
- SECSEC Form S-8 POS filed by NexImmune Inc.S-8 POS - NexImmune, Inc. (0001538210) (Filer)
- SECSEC Form S-8 POS filed by NexImmune Inc.S-8 POS - NexImmune, Inc. (0001538210) (Filer)
- SECSEC Form POS AM filed by NexImmune Inc.POS AM - NexImmune, Inc. (0001538210) (Filer)
- SECSEC Form 8-K filed by NexImmune Inc.8-K - NexImmune, Inc. (0001538210) (Filer)
- SECSEC Form 8-K filed by NexImmune Inc.8-K - NexImmune, Inc. (0001538210) (Filer)
- SECSEC Form 10-Q filed by NexImmune Inc.10-Q - NexImmune, Inc. (0001538210) (Filer)
- SECSEC Form DEFA14A filed by NexImmune Inc.DEFA14A - NexImmune, Inc. (0001538210) (Filer)
- SECNexImmune Inc. filed SEC Form 8-K: Other Events8-K - NexImmune, Inc. (0001538210) (Filer)
- SECSEC Form DEFA14A filed by NexImmune Inc.DEFA14A - NexImmune, Inc. (0001538210) (Filer)
- SECNexImmune Inc. filed SEC Form 8-K: Other Events8-K - NexImmune, Inc. (0001538210) (Filer)
- SECSEC Form DEFA14A filed by NexImmune Inc.DEFA14A - NexImmune, Inc. (0001538210) (Filer)
- SECNexImmune Inc. filed SEC Form 8-K: Other Events8-K - NexImmune, Inc. (0001538210) (Filer)
- NEWSNexImmune Shares Resume Trade Following Circuit Breaker Halt, Stock Now Up 111%
- SECSEC Form DEF 14A filed by NexImmune Inc.DEF 14A - NexImmune, Inc. (0001538210) (Filer)
- INSIDERPresident and CEO Jones Kristi bought $0 worth of Series A Preferred Stock (1 units at $0.01) (SEC Form 4)4 - NexImmune, Inc. (0001538210) (Issuer)
- SECSEC Form PRE 14A filed by NexImmune Inc.PRE 14A - NexImmune, Inc. (0001538210) (Filer)
- SECNexImmune Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits8-K - NexImmune, Inc. (0001538210) (Filer)
- NEWS12 Health Care Stocks Moving In Wednesday's After-Market SessionGainers Sharps Technology (NASDAQ:STSS) stock increased by 56.5% to $0.4 during Wednesday's after-market session. The market value of their outstanding shares is at $6.3 million. Geovax Labs (NASDAQ:GOVX) shares moved upwards by 21.71% to $2.27. The market value of their outstanding shares is at $5.2 million. NexImmune (NASDAQ:NEXI) stock increased by 9.52% to $3.45. The company's market cap stands at $4.7 million. As per the news, the Q1 earnings report came out 2 days ago. Cognition Therapeutics (NASDAQ:CGTX) stock rose 8.04% to $2.83. The market value of their outstanding shares is at $113.3 million. Clearside Biomedical (NASDAQ:CLSD) shares rose 7.39% to $1.45. The market value of t
- SECSEC Form 10-Q filed by NexImmune Inc.10-Q - NexImmune, Inc. (0001538210) (Filer)
- NEWS12 Health Care Stocks Moving In Thursday's Pre-Market SessionGainers Lucy Scientific Discovery (NASDAQ:LSDI) stock moved upwards by 123.5% to $1.14 during Thursday's pre-market session. The market value of their outstanding shares is at $2.0 million. SINTX Techs (NASDAQ:SINT) stock moved upwards by 19.67% to $0.15. The market value of their outstanding shares is at $18.7 million. As per the press release, Q1 earnings came out 3 days ago. Dynatronics (NASDAQ:DYNT) stock increased by 16.7% to $0.51. The market value of their outstanding shares is at $2.7 million. Ontrak (NASDAQ:OTRK) shares moved upwards by 15.99% to $0.31. The company's market cap stands at $14.8 million. The company's, Q1 earnings came out 2 days ago. NovaBay Pharmaceuticals (AME
- SECSEC Form NT 10-Q filed by NexImmune Inc.NT 10-Q - NexImmune, Inc. (0001538210) (Filer)
- SECSEC Form 10-K filed by NexImmune Inc.10-K - NexImmune, Inc. (0001538210) (Filer)
NEXI FAQ
7 questionsWhat does NexImmune Inc. do?
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the...Where does NEXI stock trade?
NexImmune Inc. (NEXI) is listed on NASDAQ.What sector and industry is NEXI in?
NexImmune Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did NexImmune Inc. go public?
NexImmune Inc. (NEXI) completed its IPO in 2021.What are analysts saying about NEXI?
NexImmune Inc. has had 2 recent analyst actions on file. The most recent action was from Raymond James: Outperform with a $1300.00 price target on 2022-02-22. Recent price targets range from $1300.00 to $2100.00.What companies are similar to NEXI?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NEXI side-by-side with any of them on Quantisnow.How can I track NEXI on Quantisnow?
Quantisnow aggregates NexImmune Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NEXI to receive live email and push alerts on every new disclosure.